Literature DB >> 24730439

Design and development of oral nanoparticulated insulin in multiple emulsion.

T Venkata Siddhartha, V Senthil, Ilindra Sai Kishan, Rizwan Basha Khatwal, SubbaRao V Madhunapantula1.   

Abstract

The present research aimed at developing an injection-free nanoparticulated formulation in multiple emulsion form, for oral delivery of insulin, which otherwise undergoes degradation in the gastric environment if administered orally. Insulin-polymeric nanoparticles were prepared using layer by layer (LbL) adsorption method and incorporated into an emulsion to form a nanoparticulated multiple emulsion. Using 0.6 M sodium chloride, the insulin nanoaggregates of 300-400 nm size were obtained about a yield of 94%. The characteristics of a representative nanoparticle were as follows: particle size - 391.9±0.41 nm, polydispersity index -0.425, zeta potential- +20.6 mv, encapsulation efficiency- 86.7±1.42% and percentage entrapment efficiency of the insulin-polymeric nanoparticles in the inner aqueous phase of emulsion was 84.6%. The FT-IR analysis confirms that there were no drug interactions with the polymers. Stability analysis carried out for 3 months at 8-40 °C, showed only minor changes at the end period. The release kinetics of the nanoparticulated multiple emulsion at pH 7.4 followed first order kinetics and obeyed the Fickian law. However, at pH 2.0 the release kinetics from nanoparticulated multiple emulsion followed zero order kinetics without obeying to the Fickian law. In conclusion, our data demonstrate that the nanoparticulated multiple emulsion formulation has good release characteristics and imparted a tolerable protection for insulin at different pH conditions, which may be exploited for oral administration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24730439     DOI: 10.2174/1567201811666140414115259

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  2 in total

Review 1.  Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins.

Authors:  Ying Han; Zhonggao Gao; Liqing Chen; Lin Kang; Wei Huang; Mingji Jin; Qiming Wang; You Han Bae
Journal:  Acta Pharm Sin B       Date:  2019-01-10       Impact factor: 11.413

2.  Tumor homing peptide modified liposomes of capecitabine for improved apoptotic activity and HER2 targeted therapy in breast cancer: in vitro studies.

Authors:  Mantosh Kumar Singh; Sai Kiran S S Pindiprolu; Bharat Kumar Reddy Sanapalli; Vidyasrilekha Yele; G N K Ganesh
Journal:  RSC Adv       Date:  2019-08-12       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.